WeightWatchers Files Bankruptcy as GLP-1 Drugs Reshape Market
WeightWatchers, known for its diet programs once endorsed by celebrities including Oprah Winfrey, has filed for bankruptcy after struggling to compete with weight-loss drugs like Ozempic.
The company —which rebranded to WW International Inc. — filed a prepackaged Chapter 11 petition to execute a lender-backed plan that would cut about $1.15 billion in debt from its balance sheet. It expects to complete the reorganization in about 45 days.
WeightWatchers said the restructuring plan will 'significantly reduce' its debt obligations. The proposed restructuring must be approved by a bankruptcy judge.
WeighWatchers tried to ride the weight-loss drugs wave by offering a few on its platform, but found it challenging to convince clients that its programs were still worth their time alongside the medications.
The company is seeking court protection in Delaware after Bloomberg News reported last month that WeightWatchers was preparing to file in the coming weeks following a debt-restructuring agreement with the majority of its lenders.
Prepackaged bankruptcies generally allow companies to exit Chapter 11 quickly and without disruption to their business or unsecured creditors.
WeightWatchers said the restructuring plan would retain $175 million previously drawn by the company from its revolving credit facility, reduce its annual interest expense by about $50 million and extend debt maturities.
WeightWatchers, which listed assets and liabilities each of between $1 billion and $10 billion, reported revenue of $186.6 million in the first quarter of the year, a 9.7% drop compared to a year before, dragged down by headwinds in the Behavioral business due to lower incoming subscribers and recruitment challenges. The company also reported a 14.2% decrease on its end of period subscribers for the quarter, and a net loss of $72.6 million. It didn't provide guidance for the full 2025 fiscal year.
The company will host a call with investors on Tuesday to explain the debt-cutting agreement with creditors.
With assistance from Dorothy Ma.
This article was generated from an automated news agency feed without modifications to text.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
Is Samantha Ruth Prabhu's 'meal sequencing' hack the real deal for blood sugar? Expert breaks it down
When actress Samantha Ruth Prabhu revealed how rearranging her meals stabilized her blood sugar, fans began calling it a 'game‑changer.' But is this trending 'meal sequencing' diet hack truly effective—or just another wellness fad? Upon discovering erratic glucose spikes despite clean eating, Samantha turned detective with her tracking device. She noticed that eating her plate in a specific order—vegetables first, protein next, carbs last—helped smooth out her readings. Experts dubbed this method 'food sequencing,' and suddenly, it was trending among health circles. The Science Behind the Sequence The concept isn't new. UCLA Health explains that consuming fibrous vegetables and protein before refined carbs can slow carbohydrate absorption and prevent sharp insulin surges. Particularly for those with Type 2 diabetes, research supports the stability this approach provides. — BrainMDHealth (@BrainMDHealth) Control Sugar, Control Disease Refined carbs like white rice and sugary snacks trigger fast blood sugar spikes. Immune‑boosting whole foods—think beans, legumes, leafy greens—release energy gradually and blunt glucose surges. A 2022 study cited by Nadeau even linked eating veggies first to improved HbA1C levels in diabetes patients over five years. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like AC Installation & Repair from Certified Pros Search7 Learn More The order of eating also influences fullness. Protein-first meals boost GLP‑1, a satiety hormone, delaying stomach emptying. Fiber further enhances this effect, reducing overeating. As registered dietitian Jamie Nadeau notes, natural anti‑inflammatory foods help manage chronic low‑grade inflammation that often accompanies poor diets. Expert's Verdict: Effective—but Not a Silver Bullet Acoording toa report from USA Today, dietitian Jamie Nadeau cautions against overselling the hack. 'Generally there isn't enough research to support this being a solid strategy,' she tells us. While meal sequencing may aid blood sugar control , it doesn't replace holistic diet and lifestyle habits. 'No quick fixes,' she reminds readers, especially those hoping for a shortcut to 'nature's Ozempic.' You Might Also Like: Samantha Ruth Prabhu shares one simple trick that fixed her spikes in blood sugar levels UCLA Health supports this view, adding that while meal timing can help, the strongest health gains still come from balanced eating, activity, and mindful nutrition. Should You Try It? If pairing your fork and knife in a veggie‑first order sounds manageable, go ahead. But experts stress that this technique is a small piece of a much larger wellness puzzle. The core pillars remain consistent: whole grains, lean proteins, healthy fats, and lifestyle balance. So next time you fill your plate, consider this question: Could a little shift in comfort food order help you age better, feel fuller, and keep blood sugar in check? Maybe so—but only when it joins forces with a well-rounded diet and healthy habits. You Might Also Like: Want to live longer? Forget expensive experiments; longevity doctor reveals simple secrets to a healthier, happier life
Economic Times
a day ago
- Economic Times
Eli Lilly says its anti-obesity pill matches Ozempic
New Delhi: Eli Lilly said on Saturday that its anti-obesity pill, Orforglipron, has shown significant results during clinical trials in reducing weight and lowering blood sugar in diabetes patients, comparable to Novo Nordisk's anti-diabetes drug Ozempic. The US drug maker aims to submit the Phase-III trial data to regulators by the end of this year and expects to get regulatory approvals from 2026, it said. The results were announced at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. Eli Lilly also makes blockbuster drug Tirzepatide for type-2 diabetes under the Mounjaro brand and chronic weight management under the brand Zepbound. Both are administered via injection. Orforglipron as well as Tirzepatide are GLP-1 drugs, which mimic a natural gut hormone that controls sugar levels and appetite. The 40-week trial of the new pill tested three doses of Orforglipron: 3 milligrams, 12 milligrams and 36 milligrams. All were found to be effective at lowering blood sugar, the company said. The 12 mg and 36 mg doses also showed clinically meaningful and statistically significant reductions in body weight compared to a placebo, the company said. The 36 mg dose led to an average weight loss of 7.9% over 40 weeks.
Time of India
a day ago
- Time of India
Eli Lilly says its anti-obesity pill matches Ozempic
Eli Lilly's Orforglipron, an anti-obesity pill, demonstrated significant weight loss and blood sugar reduction in clinical trials, rivaling Novo Nordisk's Ozempic. The company plans to submit Phase-III trial data to regulators by year-end, anticipating approvals from 2026. The 36 mg dose resulted in an average weight loss of 7.9% over 40 weeks. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads New Delhi: Eli Lilly said on Saturday that its anti-obesity pill Orforglipron , has shown significant results during clinical trials in reducing weight and lowering blood sugar in diabetes patients, comparable to Novo Nordisk 's anti-diabetes drug Ozempic The US drug maker aims to submit the Phase-III trial data to regulators by the end of this year and expects to get regulatory approvals from 2026, it said. The results were announced at the annual meeting of the American Diabetes Association and published in the New England Journal of Lilly also makes blockbuster drug Tirzepatide for type-2 diabetes under the Mounjaro brand and chronic weight management under the brand Zepbound. Both are administered via as well as Tirzepatide are GLP-1 drugs , which mimic a natural gut hormone that controls sugar levels and 40-week trial of the new pill tested three doses of Orforglipron: 3 milligrams, 12 milligrams and 36 milligrams. All were found to be effective at lowering blood sugar, the company 12 mg and 36 mg doses also showed clinically meaningful and statistically significant reductions in body weight compared to a placebo, the company said. The 36 mg dose led to an average weight loss of 7.9% over 40 weeks.
